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igtll clones encoding human prostatic acid phosphatase (PAP) (EC 3.1.3.2) were isolated from human prostatic cDNA 
libraries by immunoscreening with polyclonal antisera. Sequence data obtained from several overlapping clones indicated 
that the composite cDNAs contained the complete coding region for PAP, which encodes a 354-residue protein with 
a calculated molecular mass of 41 126 Da. In the S-end, the cDNA codes for a signal peptide of 32 amino acids. Direct 
protein sequencing of the amino-terminus of the mature protein and its proteolytic fragments confirmed the identity of 
the predicted protein sequence. PAP has no apparent sequence homology to other known proteins. However, both the 
cDNA clones coding for human placental alkaline phosphatase and PAP have an alu-type repetitive sequence about 900 
nucleotides downstream from the coding region in the 3’-untranslated region. Two of our cDNA clones differed from 
others at the S-ends. RNA blot analysis indicated mRNA of 3.3 kb. We are continuing to study whether acid phos- 
phatases form a gene family. as do alkaline phosphatases. 
cDNA; Acid phosphatase; mRNA; Prostatic cancer; Sequence analysis; (Human prostate) 
1. INTRODUCTION 
Acid phosphatases (orthophosphoric monoester 
phosphohydrolase, EC 3.1.3.2) are a group of iso- 
enzymes that hydrolyze phosphate esters under 
acidic conditions to yield Pi. Human prostatic acid 
phosphatase (PAP) was the first urological tumor 
marker, and its primary clinical importance still 
lies in the staging and monitoring of patients with 
prostatic adenocarcinoma [ 11. The physiological 
function of PAP has not been clarified. The 
epithelial cells of the prostate synthesize PAP and 
secrete it into the seminal fluid (to approx. 
1 mg/ml) [2]. This enzyme is under androgen 
regulation. PAP is a glycoprotein containing two 
subunits of identical size (48 kDa) [3,4]. The en- 
zyme exhibits electrophoretic heterogeneity partly 
due to variable sialic acid substitution in the carbo- 
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hydrate side chains [5]. This can also be ascribed to 
differences in amino acids in the polypeptide 
chains [6,7]. 
PAP has been suggested to possess antigenic 
properties which are present in the other acid phos- 
phatases that originate from the pancreas [8], 
spleen [9], kidney [lo], placenta 11, and neutrophil 
[ 121 and eosinophil granulocytes [ 131. However, 
monoclonal antibodies to PAP have shown that. it 
has an antigenically unique region, not present in 
acid phosphatases from other sources [14]. When 
polyclonal antisera to PAP were used, an immuno- 
reactive acid phosphatase from normal embryonic 
lung cells (WI-38 cells) was detected as a high 
molecular mass precursor of 112 kDa [lo]. In 
another study, such a precursor was not observed 
in an in vitro translation assay with WI-38 cells 
[ 151. The authors concluded that the acid phos- 
phatases from prostate and embryonic lung cells 
are immunologically related, but distinct proteins 
encoded by different genes. 
Despite the fact that the prostatic acid phos- 
phatase has now been used for 50 years as a marker 
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of prostatic cancer, the physiological importance 
and structure of this protein remain largely un- 
known. For further understanding of the clinical 
significance of PAP and the contradictory results 
obtained for heterogeneity and immunoreactivity 
of acid phosphatases, the best approach is to 
resolve the structure of PAP and other acid phos- 
phatase isoenzymes. Because PAP is an androgen- 
regulated protein of the prostate, its gene is 
suitable for further studies of androgen regulation. 
This could provide important information on the 
androgen dependency of prostatic cancer. 
Here, we have cloned and sequenced the cDNA 
encoding human PAP, in order to study its biosyn- 
thesis and androgen regulation. 
2. MATERIALS AND METHODS 
2.1. Peptide sequence analyses 
Purification of PAP was performed as in [16]. Tryptic pep- 
tides of PAP were purified by HPLC using a Vydac 218 TO 54 
column (4.6 x 250 mm). Elution (1 .O ml/mm) was achieved us- 
ing a linear gradient of acetonitrile (O-60% in 30 min) in 0.1% 
trifluoroacetic acid, and tryptic peptides were detected at 
218 nm. 
For determination of the amino-terminal sequence of the 
HPLC-purified tryptic peptides of PAP (24pg), the purified 
peptides and the protein were applied directly to a 
Polybrene/NaCl-treated glass fiber filter and degraded with a 
gas-phase sequencer (model 470A, Applied Biosystems) [17,18]; 
amino acid phenylthiohydantoin derivatives were analyzed by 
HPLC on a Spherisorb column (S5 ODS 2, 4.6 x 250 mm) us- 
ing a gradient of acetonitrile in 30 mM sodium acetate, pH 4.8 
[191. 
2.2. Construction and screening of cDNA libraries 
Total cellular RNAs were isolated from human normal pros- 
tatic tissue (cystoprostatectomy for bladder cancer), human 
benign prostatic hyperplasia tissue and human prostatic car- 
cinoma tissue as described [20]. Poly(A)+ RNAs were separated 
by chromatography on oligo(dT)-cellulose as described by Aviv 
and Leder [21]. Double-stranded cDNA was synthesized using 
a cDNA synthesis kit (Amersham) and cloned into a hgtl 1 ex- 
pression vector. Two libraries were constructed, one from 
human prostatic carcinoma tissue (CA I), the other from 
human benign prostatic hyperplasia tissue (BPH). In addition, 
we have used a prostatic carcinoma tissue cDNA library (CA II) 
constructed from our mRNA by Clontech laboratories (Palo 
Alto). 
The cDNA libraries were screened with polyclonal antibodies 
raised in rabbits against the pure PAP protein [22], using the 
Promega immunoscreening system. Putative positive clones 
were carried through two or three rounds of screening until all 
phages produced positive signals. 
2.3. Characterization of recombinant clones 
The subclonings were carried out using pBR322 (New 
276 
England Biolabs) and pUCl8 (Boehringer Mannheim) vectors. 
Plasmid DNAs were amplified in E. coli MC1061 and E. coli 
JM109 cells, respectively, and purified by a modified CsCl gra- 
dient centrifugation method [23]. Southern analysis was carried 
out according the standard procedures [23,24]. 
The EcoRI-digested inserts of recombinant hgtll cDNA 
clones were subcloned into EcoRI-cut Ml3 mpl8 vector [25]. 
DNA sequence determination was done by the dideoxy chain- 
termination method [26] with SequenaseTM enzyme [27], 17-mer 
universal primer and specific synthetic oligonucleotides. The se- 
quencing strategy is indicated in fig. 1. All sequences were deter- 
mined at least twice. Computer analyses of DNA sequences 
were performed with the MicrogenieR-sequence analysis pro- 
gram distributed by Beckman Instruments (Palo Alto). 
2.4. Hybridization of cDNA to RNA blots 
3pg of each poly(A)+ RNA was electrophoresed on 
0.7-1.0% agarose gels containing formaldehyde (2.2 M), and 
transferred to a nylon membrane (Hybond, Amersham). 
Hybridizations and washes were performed under stringent 
conditions according to the manufacturer’s recommendations. 
The double-stranded cDNA probe was labeled by nick- 
translation with [m-“P]dCTP to a specific activity of 
5 x IO8 cpm/fig. 
3. RESULTS 
3.1. Peptide sequences 
The amino-terminus of pure PAP is: Lys-Glu- 
Leu-Lys-Phe-Val-Thr-Leu-Val-Phe-Arg-His-Gly- 
(x)-Arg-Ser. The sequences of three tryptic pep- 
tides are: (I) Met-Leu-Pro-Gly-x-Ser-Pro-Ser-x- 
Pro, (II) Phe-Glu-Lys-Gly-Glu-Tyr-Phe-Val-Glu- 
Met-Tyr, (III) Phe-Ala-Glu-Leu-Val-Gly-Pro-Val- 
Ile-Pro-Gln-Asp. 
3.2. Screening of libraries and characterization of 
clones 
To clone the cDNA of PAP we screened three 
different prostatic cDNA libraries with polyclonal 
PAP-antiserum. Some of the positive clones were 
also confirmed as coding for PAP protein by im- 
munoscreening with different PAP antisera. A 
total of = 1.1 x lo6 hgtl 1 recombinants were 
screened. From the CA I library we found several 
positive clones of sizes ~250 bp. These short 
clones hybridized to each other and therefore we 
chose only our PAP-9 clone for further 
characterization. The sizes of several positive 
clones from the BPH library were determined, of 
which two, PAP-l 13 and PAP-123, both contain- 
ing an insert of about 1.6 kb, were selected for fur- 
ther characterization. From the prostate CA II 
library, recombinant clones PAP-1004, PAP-1005 
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Fig. 1. Partial restriction map and sequencing strategy of cDNAs encoding human PAP. Direction and extent of sequence determina- 
tions are indicated by arrows. The priming of sequence determinations is indicated by an open circle when the universal primer has 
been used, and synthetic oligonucleotide primed determinations are preceded by a solid circle. The protein coding region is shown by 
the open box. 
and PAP-1007, containing inserts of 2.3, 1.6 and 
0.6 kb, respectively, were chosen for sequence 
analysis. An additional clone, PAP-1006, was 
characterized from this library. When digested 
with EcoRI, it released three fragments of 0.4 
(PAP-1006B), 0.2 (PAP-1006C) and 0.8 kb 
(PAP-1006A). 
To determine the respective orientation of our 
cDNA clones (fig.l), Southern analysis was used. 
A cDNA clone, PAP-9, was subcloned into 
pBR322 plasmid and used as a hybridization 
probe. It hybridized only with PAP-1006 and 
PAP-1007. On the other hand, a 290 bp EcoRI- 
PstI fragment from PAP-1004 in pUC18 recog- 
nized PAP-123, PAP-1005 and PAP-1006. 
Because PAP-1006 hybridized with two in- 
dependently obtained cDNA clones (PAP-9 and 
PAP-1004), it is evident that its EcoRI-digested 
multiple inserts were not a cloning artefact, but the 
result of internal EcoRI sites. This could also ex- 
plain our difficulties in obtaining longer cDNA 
clones from the prostate library CA I, as apparent- 
ly the methylation step used to protect internal 
EcoRI sites had been ineffective. 
3.3. Sequence analysis of cDNA clones 
Clones PAP-9, PAP-123, PAP-1004, PAP-1006 
and PAP-1007 were sequenced entirely. Partial 
DNA sequences of PAP-113 and PAP-1005 re- 
vealed that they were identical to PAP-123. The 
combined nucleotide sequence of the overlapping 
cDNA clones was 3088 bp, containing 1905 bp of 
3 ‘-untranslated and 23 bp of 5 ‘-untranslated se- 
quences (fig.2). 
All tryptic peptides and the amino-terminal pep- 
tide were identified in the protein sequence de- 
duced from the cDNA. The amino-terminal 
peptide of 16 amino acids was coded by nucleo- 
tides 119-187. All the tryptic peptides resided in 
the carboxy-terminal part of PAP protein: nucleo- 
tides 980-1012 (amino acids 324-335); nucleotides 
1049-1078 (amino acids 3 1 I-320) and nucleotides 
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"d 0 CCCAGAAACAGCTCTCCTCAAC~AGAGCTCCTCCTGGCCAGGGCAGCAAG 
-32 MetArgAlaAlaProLeuLelieuAlaAr~AlaAlaSe 
\c/ - 
60 CTTAGCCTTGCCTTCTTGTTTCTGCTTTTTTTGCTRGACCGAAGTGTACTAGC A 
-19 rLeuAlaLeuAlaSerCysPheCysPhePheCysTrpLeuAspArgSerValLeuA1 ?k 
+1 
LetI 
C -_----___-____________________----- 
121 GGAGTTCAACTTTCTCACTTTGCTCTTTTCGGCATCGAGACCGAAGTCCCATTGACACCTT 
2 gGluLeuLvsPheValThrLeuValPheAraHisClvAspA~ProIleAspThrPh 
181 TCCCACTGACCCCATAAACCAATCCTCATGCCCACAATCCATTTCGCCAACTCACCCAGC 
22 eProThrAspProIleLysCluSerSerTrpProGlnTrplleTrpProThrH~sProA1 
:, 
241 TGGCATCGACCACCATTATCAACTTGGAGAGTATATAAGAAAGAGATATAGAAAATTCTT 
42 aCly~etCluClnH~sTyrCluLeuCiyCluTyrlleAr~LysAr~TyrAr~LysPheLe 
301 
62 
361 
a2 
421 TCCTATCCTACTCTGCCACCCCATCCCCCTGCACACACTTCCTCTTTCTCAACATCACTT 
102 nProIleLeuLeuTrpClnProllePro'~alHisThrValProLeuSerGluAs~lnLe 
481 CCTATACCTGCCTTTCAGC~ACTCCCCTCCTTTTCAACAACTTCACACTCACACTTTGAA 
122 uLeuTyrLeuProPheArgAsnCysProArgPheClnCluLeuGluSerGluThrLeuLy 
541 
142 
d 
ATCACACCAATTCCAGAAc;ACCCTCCACCCTTATAAGCATTTTATACCTACCTTCCCAAA 
sSerCluCluPheGlnLysAr~LeuH~~ProTyrLysAspPhe~~eAlaThrLeuG~yLy 
601 ACTTTCACGATTACATCCCCAGCACCTTTTTGCAATTTGCAGTAAAGTCTACGACCCTTT 
162 sLeuSerClyLcuHisClyClnAspLeuPheClyIleTrpSerLysValTyrAspAlaLe 
661 ATATTCTGACACTGTTCACAATTTCACTTTACCCTCCTGGCCCACTGAGGACACCATGAC 
182 uTyrCysCluSerValHl~p\snPheTh~euPr~SerTrpAlaThrGluAspThrUetTh 
721 
202 
:) 
TAACTTGAGACAATTCTCACAATTCTCCCTCCTGTCCCTCTATGCAATTCACAAGCAGAA 
rLysLeuArgCluLeuSerCluLeuSerLeuLeuSerLeuLe~SerLeuTyrG~yIleHisLysGlr~y 
.\ 
781 
222 
II 
AGACAAATCTAGCCTCCAAGCGCCPCTCC;CGTCAATGAAA?CCTCAATCACATGAACAG 
sCluLysSerAr~LnuC!nGlyGl~Va.LeuValAsnC:uLe~AsnH~~~etLysAr 
T\ c\ c 
ArgAsnLeJC:y 
a41 ACCAAC-CACATACCAACCTACAAAAGAC:TATCATCrATTCTGCGCATGACACTACTGT 
242 gd:,ThrCI1:leProSerTyrLys~ysL~~:~~M~tTyrSerAlaH~~AspTh~~hr~a 
901 GAGTCCCCTACACA 'XCGCTAGATGTTTACAACGCACTCCTCCTTCCTCC~TATGCTTCTTG 
262 1SerClyLeuGln~etAiaL~~Asp'~alTyrAsnCiyLe~L~~P~oProTyrAlaSerCy 
961 CC~CTTCACCGAATTCTACTTTGACARCCCGCACTACTTTGTGGAGATGTACTACCGGAA 
202 sH,sLeuThrCluLe~TyrPheCluivsClvCluTvrPhe~ialGluUetT~TyrAr~ 
1021 TCACACCCdCCACCACCCCT~TCCCCTCRTCCTACCTCCC~GCAGCCCCAGCTG~CCTCT 
,302 ~1nHlsCI~ProTyrProLeuHetLeuProGlyCvsSerProSerCysPraLe 
1081 CCACACG~TCCTCAGCTCGTTCCCCCCTCATCCCTCCCTCAAGACTGCTCCAC~AGTGTAT 
322 uCluAr~PheAlaCluLeuValGlyProValllePr~lnAs~TrpSerThrGluCys~e 
1141 CACCACAAACACCCATCAACCTACTCACTGA~ACATTCCACACACATCTCT 
342 tThrThrAsnSerH~sClnClyThrCluAspSerThrAsp 
,201 CTAGAAACACTAGCTCCCCmCTCACCCCACATCA~CAGATCATGC~GAGAACATACTTTGGCCA 
1261 TTACCCCCCACCTTTCAGGAAAATCCGCTTTCCATCATTATTTTATGTTTTAG~ACCCC 
1321 CAACCTCACGCAATTCCTACCTCTTCACCTGACCCTGCCCCCAC~GCCATAAAAC~AG 
1381 CTAAC~TGTTTTCTlTTTCAGCG~AATGTAAAGG~CACCACTGCCAAAATATAATC 
1441 ACACATAAACCTTACCTCAAACTTCATAGAGTTCCCCATGAACTATATGACT~CCACACA 
1501 GCATCTTTTCTATTTAAGCA~CTGAGA~GC~GAGCAGGA~AGATAAGTCTG~C 
1561 TTTAAATTTCTGAAATCCAACAGATTTCAAAAAAAATTCCCACAATCTACCGTCCCAACA 
1621 ACGAACCAAACATGTGAATACCCTCATCGCCAAAAAACCAAT~ACCCATCAG~CCAGC 
1681 C?TCTCTCAAGGACACCCAAAGAAACCAGATACAGTCCACACATCTCGAAACTTCTCC 
1141 ACTCCAAAACTCCTACTATCTGTTTTTATATTTCTGTTAAAATATATGAGGCTACAGAAC 
1801 TAAAAA~AAAACCTCTTTCTGTCCCTTGCTCCTGGAACRCCTTTTAAAGAA 
1861 ACAAAAATCAAACTTTACACAAAGATTTGATCTATGTAATACATATA~CAGCTCTTGAAG 
1921 TATATATATCATACCAAATAAGTCATCTGATGAGAACAAGCTATTTGGGCACAACACATC 
1981 AGCAAACACACCACCACCTCATCCACTTTCTCCACAACCTCCAGTGATAAGAGATGTTGA 
2041 CTCTAY\ACTTCA~AAU;CCACCCPiTCCTGGTTTACCGGG 
2101 c 
1 
2161 GAAACCTTGTCTCTACATAAAATACAA~ACTTACAT4;CCATGCTCCTCTGTCCCTATA 
2221 CTCCACTACTTCTGCCGCTAACGCICCRCCATCAC~GAGCCCCGGAGCTCGAGCCTACA 
2281 GTGACCCAACACTGCACTACTGTACTCCACCCA~GCAAGAGAGCGAGACCCTGTCTC~ 
2341 
-mm 
~~~~[CAACCAGDATAGGCTAGGCACGTGGCTCACACCTGTAATCCTTGCATT~GGAA~CTGA 
2461 CGCACCACCATCACTTTAGGCCTG~T~T~TTCAAGACCACA~AC 
2 
2521 ACTCTCTCTACCAAAAAAAC&AACCAA CACACATATCAAACTCAAACAAAATTAGAAA 
2581 TGTAATTATGTTATCTTCTAACTGCCTCCAACTTCAAAACTTATTCGAATCTTGAGAGTC 
2641 TGGTTACCAAATACCTTACCAGGACAAAAGGAATGTGTAAGTCTTTAATGCCGATATCTT 
2701 CAGAAAACCTAACCAAACTTACACCTCCTCCTGCTGAAACTGCCCACTCTCCAAGAAGAAATC 
2761 ATCATATAGCTTTCCATCTCCCACATCTACATCTACATGTCTACAGAACACTGTGCTCTATTACCA 
2821 TTATCGATAAAGA~GACATU;TTTCT~GAGATGGTTTC~CTCGCTGCCAGAATCTAGAG 
2801 CAAAGCCATCCCCGCTCCTGCTTCCTCACAGAATCACTCACAAACACATCCATTGATATG 
2941 CT7CTTTGTGTTATTTCCCTCCCAAGTAAATCTTTTGTCCTTGGGTCCATTTTCTATGCTT 
3001 CTAACTCTCTTCTAGCATCACCCAAATCTAAAATACTC~GTCATTATTAGCAACT 
+ 
3061 TCAAAAGCATTGCTTTTATAATGAACTTAAAAAAAAAAAAAAAAAA 
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1088-l 123 (amino acids 288-298). 
The combined cDNA clones encode a 354 amino 
acid polypeptide. A predominantly hydrophobic 
32-residue sequence, presumably the signal pep- 
tide, beginning with Met, precedes the amino- 
terminal end of PAP obtained by protein se- 
quencing. 
The clone PAP-1004 was sequenced and found 
to be identical to PAP-123 except for an additional 
839 nucleotides of 3 ‘-non-coding sequences and 
some minor differences at the 5’-end. 
The nucleotide sequence of clone PAP-1006B 
revealed a deletion of 96 bp, and some minor dif- 
ferences at the 5 ‘-end compared with PAP-1007 as 
depicted in fig.2. 
The stretch of 96 nucleotides missing in 
PAP-1006B, corresponding to 32 amino acid 
residues, could represent an alternatively spliced 
exon, although no consensus splicing sequence 
could be found bordering the deletion. On the 
other hand, the deletion, the discrepancies between 
PAP-1006B and PAP-1007, as much as those be- 
tween the 5’-end of PAP-123 and PAP-1004, 
could be due to reverse transcriptase errors during 
cDNA synthesis. Finally, at this stage we cannot 
exclude possible genetic polymorphism of the 
PAP-gene locus as the cause of these 
dissimilarities. 
The 3 ‘-non-translated region of PAP-cDNA 
contains two human &-type repetitive sequences 
[28,29]. The first repeat extends from nucleotide 
2046 to 2398 and is composed of two ah 
monomers. It is flanked by a directly repeated se- 
quence AAG/cTTGATT at both ends. Immediate- 
ly following the first ah repeat there is an afu 
monomer starting at nucleotide position 2401 and 
ending at nucleotide position 2548. The latter ah 
repeat is surrounded by the sequence 
GAAGGA(A)G at extreme ends. The ah repeats 
share 81 and 73% homologies with the alu consen- 
Table 1 
Total amino acid composition of PAP 
Amino acid Residues per mol% mol% mol% 
polypeptide predicted [31 141 
deduced from from cDNA 
cDNA 
Alanine 12 
Arginine 15 
Asparagine and 
aspartate 25 
Cysteine 6 
Glutamate and 
glutamine 45 
Glycine 17 
Histidine 14 
Isoleucine 15 
Leucine 42 
Lysine 19 
Methionine 10 
Phenylalanine 14 
Proline 26 
Serine 27 
Threonine 24 
Tryptophan 8 
Tyrosine 19 
Valine 16 
Total 354 
3.4 3.5 3.5 
4.2 4.0 4.3 
7.0 7.0 8.6 
1.7 2.0 2.0 
12.7 13.0 13.9 
4.8 5.0 6.7 
4.0 3.5 3.7 
4.2 3.5 3.7 
Il.9 12.0 12.2 
5.4 5.0 5.5 
2.8 2.6 4.0 
4.0 4.0 4.4 
7.3 7.0 6.9 
7.6 7.0 6.8 
6.8 7.6 6.8 
2.3 2.0 ND 
5.4 5.0 2.1 
4.5 4.0 4.3 
ND, not determined. The amino acid composition derived from 
cDNA is as depicted in fig.2 
sus sequence of Schmid and Jelinek [28]. The A- 
rich 3 ‘-flanking sequence of the first ah repetitive 
element is composed of 12 (TAAA) repeats con- 
stituting a series of overlapping polyadenylation 
signals (AATAAA). In clone PAP-123, the 
poly(A) tail begins after two (TAAA) repeats after 
nucleotide 2349, whereas in an otherwise identical 
clone, PAP-1005, the 3 ‘-untranslated sequence ex- 
tends to nucleotide 2377, thus containing 9 
(TAAA) repeats (see fig.2). It is possible that the 
3 ‘-end of these cDNA clones may reflect 
heterogenity in PAP mRNAs caused by differen- 
Fig.2. DNA sequence and deduced amino acid sequence of the PAP cDNA clones. Numbering of nucleotide positions and amino acid 
residues are given at the beginning of each line. A vertical line precedes amino acid + 1, the most amino-terminal residue of native 
PAP. The sequenced peptides are underlined with a thin solid line and potential glycosylation sites Ans-X-Thr/Ser are boxed. Two 
alu-type repeats in the 3 ’ untranslated region are indicated by a solid line above the sequence and the direct repeats bordering them 
are boxed and numbered. Polyadenylation sites AATAAA are underlined with a thick solid line. A 13 bp direct repeat is indicated 
by arrows. The 5’-ends of several clones are given: (a) PAP-1007, (b) PAP-1006B, (c) PAP-9, (d) PAP-1006C, (e) PAP-123, (f) 
PAP-1004. Vertical arrows mark the beginning of the poly(A) tract in various clones. Two internal EcoRI sites are indicated by * and 
a site closely resembling the EcoRI site by +. Differences in sequence between PAP-1006B and PAP-1007 are shown above and those 
between PAP-123 and PAP-1004 beneath the assembled sequence. Deletions are marked with a broken line; V denotes insertions and 
substituted bases are written over the sequences. 
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tial use of poly(A) addition sites. Furthermore, at 
nucleotide position 3038-3044, 44 nucleotides up- 
stream of the polyadenylation site of clone 
PAP-1004 there is a canonical polyadenylation 
signal AATAAA. 
3.4. Analysis of PAP protein 
Our cDNAs encode 354 amino acids, corre- 
sponding to a molecular mass of 41126 Da. In 
previous studies the molecular mass of PAP has 
been determined to range from 46 to 52 kDa 
[3,4,30]. In vitro translation assays of human 
prostatic poly(A)+ RNA demonstrate that PAP is 
synthesized as a 43 kDa preprotein that is process- 
ed to a 41 kDa protein [15]. This is in agreement 
with our results. The difference of 5-11 kDa in 
molecular mass between the 41 kDa protein and 
native PAP is explained by glycosylation of PAP. 
NMR studies have revealed that three oligosac- 
charide side chains are linked to asparagine 
residues on PAP [5]. Three putative asparagine- 
linked glycosylation sites were found in our PAP 
sequence: Asn-Glu-Ser (residues 62-64), Asn-Phe- 
Thr (residues 188-190) and Asn-Glu-Thr (residues 
301-303). The first and third sites are in hydro- 
philic regions whereas the second is located in 
slightly hydrophobic environment. The amino acid 
distribution as calculated from the deduced se- 
quence is in agreement with published results [3,4] 
(table 1). Although over a third of PAP is com- 
posed of hydrophobic residues, no evident 
membrane-anchoring domain [31] can be found in 
the coding region. 
3.5. RNA blot analysis 
Poly(A)+ RNA obtained from human BPH 
tissue, CA tissue and normal prostatic tissue 
(cystoprostatectomy for bladder cancer) was sub- 
jected to RNA blot analysis. As a control we used 
poly(A)+ RNA from human placenta. The total 
RNA yields were about 200-500,~~g RNA/g in 
prostatic tissues and about 1000 pug RNA per g in 
placenta. After two cycles of oligo(dT)-cellulose 
chromatography, poly(A)+ RNA yields ranged 
from 1.5 to 5.0% of total RNA. The hybridization 
probe was an EcoRI-PstI fragment of our 
PAP-1004 clone (fig.1). This probe recognized a 
discrete mRNA band of 3.3 kb in all prostatic 
poly(A)+ RNAs. It did not hybridize to any placen- 
tal mRNA (fig.3). The PAP-9 insert in pBR322 
280 
28 s 
18 S 
Fig.3. Autoradiogram of RNA blot analysis. Human poly(A)+ 
RNA from prostatic tissues and placenta were electrophoresed 
in a 0.7% agarose gel containing 2.2 M formaldehyde, blotted 
onto nylon, and hybridized with 32P-labeled PAP-1004 frag- 
ment. Lanes: 1, placenta (3 fig); 2, normal prostate (1 pg); 3, 
BPH (3 pg); 4, CA (3 pg); 5, normal prostate (3 pg). Positions 
of 28 S and 18 S rRNAs are indicated. 
recognized an mRNA of the same size (not shown). 
In the BPH poly(A)+ mRNA sample (fig.3, lane 
3), a diffuse area of hybridization centered at 
2.8 kb can be seen. This could correspond to some 
other species of PAP mRNA, or simply to its 
degradation products. 
4. DISCUSSION 
Several overlapping cDNA clones encoding 
human PAP were isolated from human prostatic 
cDNA libraries. The size of our PAP cDNA was 
3088 nucleotides, covering the entire coding region 
of PAP mRNA plus 1905 nucleotides of 
3 ‘-untranslated regions. The 1065 nucleotides of 
the coding region give rise to a polypeptide of 354 
amino acids. The molecular mass of this non- 
glycosylated protein is 41 kDa. An amino-terminal 
peptide of 16 residues and three tryptic peptides 
were found in the protein sequence. 
Recently Yeh and co-workers [32] reported 
cDNA clones from a liver cDNA library which 
they assumed to code for prostatic acid phos- 
phatase. However, the restriction map of their 
clone contains an XbaI site about 300 bp upstream 
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of a BglII site, while in our cDNA clones there are 
only three XbaI sites at the 3’-end. Furthermore, 
they reported additional BglII sites, where we 
found only one site for BglII (see fig. 1). Although 
we cannot compare the sequences of their clones 
(no published data available) with our cDNA se- 
quence, it seems that their clones correspond to 
some other mRNA species rather than the PAP 
mRNA of our clones. 
A homology search of our cDNA and derived 
protein sequence was carried out against the 
Genetic Sequence Data Bank (Gen Bank, release 
no. 52 of 30.9.1987) and The National Biomedical 
Research Foundation (NBRF) Protein Data Bank 
(release no. 13 of 30.9.1987). No significant 
homologies were found. The overall structure of 
placental alkaline phosphatase cDNA [33] closely 
resembles that of PAP cDNA. Both contain an 
alu-type repetitive sequence in the 3 ‘-untranslated 
region, about 900 nucleotides downstream from 
the coding region. However, when PAP cDNA 
was compared with alkaline phosphatase genes, it 
was interesting to note that no homology at the 
nucleotide level could be found, except for the ah 
repeats. 
PAP protein is reported to consist of two sub- 
units [3,4]. It is not known whether the subunits 
are identical [7,8]. Two of our cDNA clones, 
PAP-1006B and PAP-1004, isolated from the car- 
cinoma cDNA library, differed from other cDNAs 
at their 5 ‘-ends. One possible explanation for the 
differences is that they might code for slightly dif- 
ferent subunits of PAP. This can be answered by 
further studies of the PAP gene. It will be in- 
teresting to clarify the biosynthesis of different 
PAP isoenzymes and discover whether acid phos- 
phatases form a gene family, as do alkaline phos- 
phatases [34]. 
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